Unapproved regenerative medicine for spinal cord injury in Japan
Authors:
- Yuichiro UkonYUYuichiro Ukon
- Hideyuki HakuiHHHideyuki Hakui
- Satoshi HosoyaSHSatoshi Hosoya
- Kazuki MoritaKMKazuki Morita
- Hirokazu MaeHMHirokazu Mae
- Yuya KanieYKYuya Kanie
- Masayuki FuruyaMFMasayuki Furuya
- Takahito FujimoriTFTakahito Fujimori
- Kiyoshi OkadaKOKiyoshi Okada
- Akira MyouiAMAkira Myoui
- Seiji OkadaSOSeiji Okada
Open Access
- 25 May 2026
- journal article
- review article
- Published by Elsevier in Regenerative Therapy
- Vol. 32, 101132
Abstract
No abstract availableKeywords
Funding Information
- Terumo Foundation for Life Sciences and Arts
- Japan Society for the Promotion of Science (23K15689)
This publication has 12 references indexed in Scilit:
- Cell therapy for stroke and spinal cord injury in clinical trialsStem Cells Translational Medicine, 2026
- Detailed revisions to the subordinate regulation following the amendment of the Act on the Safety of Regenerative Medicine in JapanRegenerative Therapy, 2025
- The impact of revised regenerative medicine regulations on unapproved gene therapies in JapanMolecular Therapy, 2025
- Regenerative medicine in Obstetrics & Gynecology: Current status under the Act on the Safety of Regenerative Medicine in JapanRegenerative Therapy, 2024
- Identification of unapproved orthopedic regenerative medicine: Usefulness of the Act on Safety of Regenerative MedicineStem Cell Reports, 2024
- Establishment of the National Consortium for Regenerative Medicine and National Regenerative Medicine Database in JapanClinical Therapeutics, 2018
- Astrocyte reactivity and astrogliosis after spinal cord injuryNeuroscience Research, 2018
- Traumatic Spinal Cord Injury—Repair and RegenerationNeurosurgery, 2017
- Selling Stem Cells in the USA: Assessing the Direct-to-Consumer IndustryCell Stem Cell, 2016
- New Japanese Initiatives on Stem Cell TherapiesCell Stem Cell, 2015